Acquisition - March 30, 2026
Insilico Medicine and Lilly enter R&D collaboration
Insilico Medicine has announced a drug discovery collaboration with Eli Lilly and Company (Lilly) that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.
Global report - March 30, 2026
Scientists Fighting Back
Many observers and most of the scientific community agree; the outlook for scientific research in the US has never been more uncertain.
Acquisition - February 9, 2026
Lilly to acquire Orna Therapeutics to advance cell therapies
Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell therapies that can treat underlying disease.
Global report - February 9, 2026
Innovent and Lilly in strategic collaboration
Innovent Biologics has announced a strategic collaboration with Eli Lilly and Company ("Lilly") to advance novel medicines in oncology and immunology.
Global report - January 30, 2026
AstraZeneca enhances its weight management portfolio
AstraZeneca has entered a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.
Business article - January 29, 2026
AstraZeneca plans to invest USD 15 billion in China through 2030
This investment will expand medicines manufacturing and R&D in China and leverage the country’s scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations.
